Three-Dimensional Structures of PDE4D in Complex with Roliprams and Implication on Inhibitor Selectivity (original) (raw)
Implications of PDE4 structure on inhibitor selectivity across PDE families
Hengming Ke
International Journal of Impotence Research, 2004
View PDFchevron_right
PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes
Letizia Crocetti
International Journal of Molecular Sciences
View PDFchevron_right
Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity
Swapnil Sharma
Bioorganic & Medicinal Chemistry Letters, 2014
View PDFchevron_right
Identification of a potent new chemotype for the selective inhibition of PDE4
Amanda Skoumbourdis, Noel Southall
Bioorganic & Medicinal Chemistry Letters, 2008
View PDFchevron_right
Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B
Hengming Ke
Protein Science, 2001
View PDFchevron_right
CDP840: a novel inhibitor of PDE-4
David Howat
Cell biochemistry and biophysics, 1998
View PDFchevron_right
Cyclic Nucleotide Phosphodiesterase PDE1C1 in Human Cardiac Myocytes
Vincent Florio
Journal of Biological Chemistry, 2007
View PDFchevron_right
Synergic PDE3 and PDE4 control intracellular cAMP and cardiac excitation-contraction coupling in a porcine model
amir hodzic
Journal of Molecular and Cellular Cardiology, 2019
View PDFchevron_right
Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3 and Their Contribution to cAMP Hydrolytic Activity in Subcellular Fractions of Human Myocardium
Vincent Manganiello
Journal of Biological Chemistry, 2005
View PDFchevron_right
PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization
David Adams
Biochemical Journal, 2003
View PDFchevron_right
Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)
George Baillie
Biochemical Pharmacology, 2013
View PDFchevron_right
Pharmacological potential of PDE5 inhibitors for the treatment of Cystic Fibrosis
teresinha leal
View PDFchevron_right
The Crystal Structure of AMP-Bound PDE4 Suggests a Mechanism for Phosphodiesterase Catalysis † , ‡
Hengming Ke
Biochemistry, 2003
View PDFchevron_right
Modified cAMP Derivatives: Powerful Tools in Heart Research
János Magyar
Current Medicinal Chemistry, 2011
View PDFchevron_right
Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases
Erik Schwiebert
Proceedings of the National Academy of Sciences
View PDFchevron_right
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity
Christopher Rithner
Journal of Medicinal Chemistry, 1987
View PDFchevron_right
The role of tryptophan 1072 in human PDE3B inhibitor binding
Giovanna Scapin
Biochemical and Biophysical Research Communications, 2003
View PDFchevron_right
1, 5-Substituted nipecotic amides: Selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability
Karen Houseknecht
Bioorganic & medicinal …, 2011
View PDFchevron_right
Structure-Based Discovery of Highly Selective Phosphodiesterase-9A Inhibitors and Implications for Inhibitor Design
Hengming Ke
Journal of Medicinal Chemistry, 2012
View PDFchevron_right
Combined ligand based pharmacophore modeling, virtual screening methods to identify critical chemical features of novel potential inhibitors for phosphodiesterase-5
Chandrasekaran Meganathan
Journal of the Taiwan Institute of Chemical Engineers, 2011
View PDFchevron_right
Treatment of Cardiovascular Dysfunction With PDE5-Inhibitors – Temperature Dependent Effects on Transport and Metabolism of cAMP and cGMP
Georg Sager
Frontiers in Physiology, 2021
View PDFchevron_right
Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca2+responses in endothelial cells
C. Lugnier
British Journal of Pharmacology, 2008
View PDFchevron_right
PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response
Sebastian Baś
Naunyn-Schmiedeberg's Archives of Pharmacology, 2017
View PDFchevron_right
Helix-1 of the cAMP-specific phosphodiesterase PDE4A1 regulates its phospholipase-D-dependent redistribution in response to release of Ca2+
Tom Houslay
Journal of Cell …, 2006
View PDFchevron_right
Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process
Morten Praestegaard
Cellular Signalling, 2003
View PDFchevron_right
Toward the identification of the cardiac cGMP inhibited-phosphodiesterase catalytic site
Raffaella Boggia
Journal of computer-aided molecular design, 1998
View PDFchevron_right
Cloning and Characterization of the Human and Mouse PDE7B, a Novel cAMP-Specific Cyclic Nucleotide Phosphodiesterase
Mark Fidock
Biochemical and Biophysical Research Communications, 2000
View PDFchevron_right
The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10
Howard Robinson
Journal of Molecular Biology, 2007
View PDFchevron_right
Kinetic and Structural Studies of Phosphodiesterase-8A and Implication on the Inhibitor Selectivity † ‡
Howard Robinson
Biochemistry, 2008
View PDFchevron_right
Discovery of oral and inhaled PDE4 inhibitors
Chander Celly
Bioorganic & Medicinal Chemistry Letters, 2013
View PDFchevron_right
Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode
Margarete Neu
Bioorganic & Medicinal Chemistry, 2009
View PDFchevron_right
Novel Roflumilast analogs as soft PDE4 inhibitors
Dirk Leysen
Bioorganic & Medicinal Chemistry Letters, 2014
View PDFchevron_right